1.63
-0.02 (-1.21%)
| Previous Close | 1.65 |
| Open | 1.62 |
| Volume | 583,676 |
| Avg. Volume (3M) | 1,446,375 |
| Market Cap | 116,076,136 |
| Price / Sales | 17.74 |
| Price / Book | 2.63 |
| 52 Weeks Range | |
| Earnings Date | 10 Mar 2026 |
| Operating Margin (TTM) | -9,653.85% |
| Diluted EPS (TTM) | -0.340 |
| Quarterly Revenue Growth (YOY) | -12.20% |
| Total Debt/Equity (MRQ) | 24.34% |
| Current Ratio (MRQ) | 4.93 |
| Operating Cash Flow (TTM) | -49.55 M |
| Levered Free Cash Flow (TTM) | -27.61 M |
| Return on Assets (TTM) | -31.37% |
| Return on Equity (TTM) | -36.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Ovid Therapeutics Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.25 |
|
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 16.31% |
| % Held by Institutions | 55.97% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ally Bridge Group (Ny) Llc | 31 Dec 2025 | 1,785,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 4.00 (LifeSci Capital, 145.40%) | Buy |
| Median | 3.00 (84.05%) | |
| Low | 2.00 (HC Wainwright & Co., 22.70%) | Buy |
| Average | 3.00 (84.05%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 1.74 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 22 Dec 2025 | 2.00 (22.70%) | Buy | 1.79 |
| LifeSci Capital | 22 Dec 2025 | 4.00 (145.40%) | Buy | 1.79 |
| Roth Capital | 11 Dec 2025 | 3.00 (84.05%) | Buy | 1.65 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 18 Dec 2025 | Announcement | Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |